Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused
Completed
This early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC